Repligen Corporation (NASDAQ:RGEN) reported double-digit second-quarter revenue growth and increased its full-year 2026 financial guidance, citing strong order momentum and continued market outperformance while highlighting its pending acquisition of BioLife Solutions.
Key Investor Takeaways
- Repligen raised its full-year 2026 guidance following stronger first-half performance and continued order momentum.
- Q2 revenue increased 12% year over year to $204 million, with 13% organic growth, while adjusted EPS rose to $0.54 from $0.37.
- Repligen (NASDAQ:RGEN) continues to expand its cell therapy strategy through its planned acquisition of BioLife Solutions.
- Adjusted operating margin improved to 16.7% from 12.0%, reflecting stronger profitability despite lower GAAP earnings per share.
- Updated guidance points to 10%–13% reported revenue growth and adjusted diluted EPS of $2.03–$2.09 for fiscal 2026.
Why RGEN Stock Is in Focus
Repligen reported second-quarter revenue of $204 million, up 12% from a year earlier, while delivering 13% organic growth. Management attributed the performance to continued order momentum, portfolio diversification, and disciplined execution.
On a GAAP basis, operating income remained flat at $14 million, while diluted EPS declined to $0.09 from $0.26 in the prior-year quarter. However, adjusted results improved significantly, with adjusted operating income rising to $34 million from $22 million and adjusted diluted EPS increasing to $0.54 from $0.37.
The company also raised its full-year 2026 outlook. Repligen now expects revenue between $813 million and $835 million, representing reported growth of 10% to 13% and organic growth of 10.5% to 13.5%. Adjusted diluted EPS is projected to range from $2.03 to $2.09.
Separately, Repligen highlighted its pending acquisition of BioLife Solutions, which management said will strengthen its position in the cell therapy market by adding a recurring consumables business with established customer relationships.
Why This Matters for Investors
The combination of accelerating organic growth and higher full-year guidance suggests demand for Repligen’s bioprocessing portfolio remains healthy despite a challenging industry backdrop.
The improvement in adjusted profitability, including higher operating and EBITDA margins, may reinforce confidence that the company is benefiting from operating leverage as revenue expands. Meanwhile, the planned BioLife Solutions acquisition could broaden Repligen’s exposure to the growing cell therapy market while adding complementary products and recurring revenue streams.
Although GAAP earnings declined year over year, investors may focus more closely on the stronger adjusted financial performance and management’s decision to raise guidance, which signals increased confidence in the company’s outlook.
What to Watch Next
Investors will likely monitor the completion of the BioLife Solutions acquisition, continued organic growth trends, and whether Repligen delivers on its updated revenue and earnings guidance during the second half of 2026. Additional updates on margin expansion and integration plans for the acquisition may also be key catalysts.